cyanocobalamin
Trade name: berocca
Approved
Jul 28, 1947
Cyanocobalamin is a form of vitamin B12 used to treat and prevent vitamin B12 deficiency except in the presence of cyanide toxicity. The deficiency may occur in pernicious anemia, following surgical removal of the stomach, with fish tapeworm, or due to bowel cancer. It is used by mouth, by injection into a muscle, or as a nasal spray. — Wikipedia
Clinical trial activity
110 trials · 152 clinical orgs · 54 marketing orgs
Earliest trial started May 1, 1993 (NCT00000541)
Timeline
1940s
- Jul 28, 1947
Roche — Earliest FDA Approval
- Jul 28, 1947
Roche — Marketing Organization
- Jul 28, 1947
Roche — NDA Organization
- Sep 15, 1949
Bayer — NDA Secondary Org
- Dec 6, 1949
Warner Chilcott — Marketing Organization
- Dec 6, 1949
Warner Chilcott — NDA Secondary Org
1950s
- Sep 29, 1950
Bristol-Myers Squibb — NDA Secondary Org
- Feb 20, 1953
Hospira — Marketing Organization
- Feb 20, 1953
Hospira — NDA Secondary Org
- Jul 14, 1958
Belmar Pharmacy — NDA Secondary Org
1960s
- Jun 21, 1968
Mallinckrodt — Marketing Organization
- Jun 21, 1968
Mallinckrodt — NDA Secondary Org
1970s
- Dec 21, 1970
Bracco — Marketing Organization
- Dec 21, 1970
Bracco — NDA Secondary Org
- Oct 20, 1971
West-Ward Pharmaceutical — Marketing Organization
- Apr 26, 1972
Sankyo — Marketing Organization
- Apr 26, 1972
Lutipold — Marketing Organization
- Sep 20, 1972
Accord Research — Marketing Organization
- Mar 21, 1973
American Home Products — Marketing Organization
- Jun 20, 1973
Fresenius — Marketing Organization
- Jun 22, 1973
Del Laboratories — Marketing Organization
- Jul 9, 1973
Eli Lilly — Marketing Organization
- Jan 29, 1974
Watson Pharmaceuticals — Marketing Organization
- Jan 29, 1974
Dr. Reddy's Laboratories — Marketing Organization
- Jun 10, 1974
General Electric — Marketing Organization
- Jun 10, 1974
General Electric — NDA Secondary Org
- Sep 12, 1979
Lyphomed, Inc. — Marketing Organization
1980s
- Feb 22, 1980
Armour & Company — Marketing Organization
- Feb 22, 1980
Armour & Company — NDA Secondary Org
- Nov 6, 1981
Abraxis — Marketing Organization
- Nov 6, 1981
Abraxis — NDA Secondary Org
- Apr 7, 1982
Sanofi-Aventis — Marketing Organization
- Jul 13, 1982
Watson Pharmaceuticals — NDA Secondary Org
1990s
- Jan 1, 1993
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1996
Earliest Phase 3 Sponsor(trial)
- Nov 5, 1996
Endo Pharmaceuticals — Marketing Organization
- Nov 5, 1996
Par Pharmaceuticals — NDA Secondary Org
2000s
- May 18, 2000
Sandoz — Marketing Organization
- May 18, 2000
Sandoz — NDA Secondary Org
- May 18, 2000
Novartis — NDA Secondary Org
- Sep 23, 2003
Mylan — Marketing Organization
- Jan 31, 2005
Endo Pharmaceuticals — NDA Secondary Org
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
- Jul 27, 2007
PH HEALTH — Marketing Organization
2010s
- Dec 11, 2015
Somerset Pharmaceuticals — Marketing Organization
- Jun 5, 2017
PHARMOBEDIENT — Marketing Organization
- Dec 18, 2018
Vitruvias Therapeutics — Marketing Organization
2020s
- Sep 9, 2020
Perrigo — Marketing Organization
- Sep 9, 2020
Padagis Us — Marketing Organization
- Sep 24, 2020
Gland Pharma Ltd — Marketing Organization
- Sep 24, 2020
Fosun — Marketing Organization
- Dec 8, 2020
Aurobindo Pharma — Marketing Organization
- Dec 8, 2020
Eugia Pharma — Marketing Organization
- Jan 4, 2021
Novartis — Marketing Organization
- Aug 20, 2021
Exeltis — Marketing Organization
- Apr 15, 2022
Sola Pharms — Marketing Organization
- Apr 15, 2022
Zydus Discovery DMCC — Marketing Organization
- Nov 15, 2022
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Nov 15, 2022
Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization
- Jun 30, 2023
Lupin — Marketing Organization
- Jul 10, 2024
Mankind Pharma — Marketing Organization
- Nov 15, 2024
Nanjing King-Friend — Marketing Organization
- Nov 15, 2024
Meitheal — Marketing Organization
- Apr 9, 2026
Apotex — Marketing Organization
Indications
Approved for
Studied for
- Adiposity · Phase 4
- Alzheimer Disease · Phase 3
- Asthma · Phase 2
- Atherosclerosis · Phase 2/Phase 3
- Bariatric Surgery · Phase 2/Phase 3
- Brain Edema · Phase 2
- Brain Neoplasms · Phase 2
- BRCA1 Protein · Phase 2
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Transitional Cell · Phase 2
- Cardiovascular Diseases · Phase 4
- Cerebral Infarction · Phase 3
- Cognitive Dysfunction · Phase 1
- Coronary Artery Disease · Phase 3
- Coronary Disease · Phase 2
- Depression · Phase 2/Phase 3
- Depressive Disorder · Phase 2
- Diabetic Retinopathy · Phase 4
- Diarrhea · Phase 2
- DNA, Mitochondrial · Phase 1
- Drug Evaluation · Phase 2
- Dyslipidemias · Phase 4
- Endothelial Cells · Phase 2
- Flaviviridae Infections · Phase 4
- Glucose Intolerance · Phase 4
- Head and Neck Neoplasms · Phase 2
- Heart Diseases · Phase 2
- Heart Rate · Phase 1
- Hepatitis B, Chronic · Phase 4
- Hepatitis C · Phase 4
- Hepatitis C, Chronic · Phase 4
- HIV · Phase 2
- Hodgkin Disease · Phase 1/Phase 2
- Hyperhomocysteinemia · Phase 4
- Hypertension · Early Phase 1
- Inflammation · Phase 1
- Iron Deficiencies · Phase 4
- Low Back Pain · Phase 4
- Lung Neoplasms · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, Primary Cutaneous Anaplastic Large Cell · Phase 1
- Lymphoma, T-Cell · Phase 2
- Lymphoma, T-Cell, Cutaneous · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Mastocytosis · Phase 1
- Menopause · Phase 4
- Mental Health · Phase 2/Phase 3
- Mesothelioma · Phase 2
- Mesothelioma, Malignant · Phase 2
- Mutation · Phase 2
- Mycobacterium tuberculosis · Phase 3
- Mycosis Fungoides · Phase 1
- Myocardial Infarction · Phase 4
- Myocardial Ischemia · Phase 2
- Myocardial Stunning · Phase 4
- Nasopharyngeal Neoplasms · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 4
- Obesity · Phase 4
- Osteoporosis · Phase 1
- Pancreatic Neoplasms · Phase 2
- Parkinson Disease · Phase 2/Phase 3
- Pharmacokinetics · Phase 4
- Pharmacology · Phase 1
- Pleura · Phase 2
- Pneumonia · Phase 2
- Polycystic Ovary Syndrome · Phase 4
- Prehypertension · Phase 2
- Prostatic Neoplasms · Phase 2
- Psoriasis · Phase 3
- RNA Virus Infections · Phase 4
- Schizophrenia · Phase 4
- Sepsis · Phase 3
- Sezary Syndrome · Phase 1
- Shock, Septic · Phase 3
- Steatitis · Phase 4
- Stomatitis · Phase 2
- Stroke · Phase 4
- Urinary Bladder Neoplasms · Phase 2
- Vertigo · Phase 4
- Vitamin B 12 Deficiency · Phase 4
- Waldenstrom Macroglobulinemia · Phase 1/Phase 2
Mechanism of action
- Unspecified targetOTHER
Supplement
- CubilinSupplementation
CUBN supplementation
Combination products
berocca pn
with vitamin e, folic acid, vitamin c, nicotinamide, thiamine, biotin, panthenol, pyridoxine, riboflavin, vitamin a, ergocalciferol
Also known as m.v.c, mvc plus
depinar
with tannic acid, zinc dichloride
dicopac
infuvite
with vitamin d3, vitamin e, folic acid, vitamin c, nicotinamide, thiamine, vitamin k, biotin, panthenol, pyridoxine, riboflavin, vitamin a
Also known as infuvite pediatric, infuvite pediatric (pharmacy bulk package)
m.v.i. adult (pharmacy bulk package)
with vitamin e, folic acid, vitamin c, nicotinamide, thiamine, vitamin k, biotin, panthenol, pyridoxine, riboflavin, vitamin a, ergocalciferol
m.v.i. pediatric
with vitamin e, folic acid, vitamin c, nicotinamide, thiamine, biotin, panthenol, pyridoxine, riboflavin, vitamin a, phytonadione, ergocalciferol
vitape
with vitamin e, folic acid, vitamin c, nicotinamide, thiamine, pantothenic acid, biotin, pyridoxine, riboflavin, vitamin a, phytonadione, ergocalciferol
Approval history
- approvedJul 28, 1947
Chemistry & pharmacology
SMILES
[57Co+3].[C-]#N.C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)C2[N-]C1=C(C)C3=NC(=CC4=NC(=C(C)C5=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)C(C)(C)[C@@H]3CCC(N)=O)OP([O-])(=O)O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)N7C=[NH]C8=CC(C)=C(C)C=C78- Mol. weight
- 1356.4 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral, Topical
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
Yes
Sources
- WikipediaCyanocobalamin ↗
- ChEMBLCHEMBL2110563 ↗
- ChEMBLCHEMBL2375172 ↗
- NCATSP6YC3EG204 ↗
- NCATS562RS6MC22 ↗
- NCATS025P9I542Y ↗
- NCATSU0E93N6V2A ↗
Also known as
- behepan
- behepan
- berubigen
- berubigen
- betalin 12
- calomist
- calomist
- cobamin
- cobavite
- cobavite
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamin
- cyanocobalamine
- cyanocobalamine
- cyanocob(iii)alamin
- cyanocob(iii)alamin
- cyanovit-b12
- cycobemin
- cycobemin
- cytacon
- cytacon
- cytamen
- cytamen
- nascobal
- nascobal
- redisol
- redisol
- rubivite
- rubivite
- rubramin
- rubramin
- rubramin pc
- rubramin pc
- ruvite
- ruvite
- vibalt
- vibalt
- vibisone
- vibisone
- vitamin b12
- vitamin b12
- vitamin b12
- vitamin b12
- vitamin b12
- vitamin b12
- vitamin b 12
- vitamin b 12
- vitamin b12a
- vitamin b12a
- vitamin b-12b
- vitamin b-12b
- vitamin b12 complex
- vitamin b12 complex
- vitamin b12 nos
- vitamin b12 nos
- vitamins b12
- vi-twel
- vi-twel
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06966856 | Phase 3 | Dec 30, 2026 | Tanta University |
| NCT07004465 | N/A | Aug 19, 2025 | Karbala University |
| NCT07029698 | Phase 4 | Apr 16, 2025 | Medice Arzneimittel Pütter GmbH & Co KG |
| NCT06517823 | Phase 3 | Apr 26, 2024 | Clinical Research Institute S.C., Laboratorios Silanes S.A. de C.V. |
| NCT06186154 | Phase 1 | Jan 31, 2024 | University of British Columbia |
| NCT05785585 | N/A | Sep 9, 2023 | Eurecat, Laboratorio Echevarne |
| NCT05221892 | Phase 4 | Nov 22, 2021 | Fundação Educacional Serra dos Órgãos |
| NCT05005897 | Phase 2/Phase 3 (Phase 3) | Oct 15, 2021 | Inland Norway University of Applied Sciences, Sykehuset Innlandet HF, University of Bergen, University of Oslo |
| NCT04387201 | Phase 4 | May 15, 2020 | University of Texas at Houston |
| NCT04150042 | Phase 2 | Mar 31, 2020 | General Oncology, Inc. |
| NCT04197115 | Phase 3 | Sep 1, 2019 | IMSS Hospital General de Zona 11 |
| NCT04585334 | Phase 4 | Mar 25, 2019 | Fidia Advanced Biopolymers |
| NCT03877523 | N/A | Oct 3, 2018 | Institute for Atherosclerosis Research, Russia |
| NCT03437824 | Early Phase 1 (Phase 1) | Oct 1, 2017 | University of Southern California |
| NCT02693717 | Phase 2 | May 9, 2017 | Eli Lilly, University of Texas at Houston |
| NCT02786823 | Phase 2/Phase 3 (Phase 3) | May 1, 2017 | All India Institute of Medical Sciences |
| NCT02934438 | N/A | Oct 1, 2016 | HumanN, Methodist Cancer Center, Houston, Texas |
| NCT02837367 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2016 | Romania:The National Authority for Scientific Research, University of Medicine and Pharmacy Victor Babes Timisoara |
| NCT02735317 | Phase 2 | Apr 1, 2016 | Sun Yat-Sen University |
| NCT02773147 | Phase 2 | Apr 1, 2016 | University of Gothenburg |
Organizations
Research & Development (152)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spectrum Pharmaceuticals | For profit | 8 | 8 | 2 | 2007 |
| Eli Lilly | For profit | 7 | 3 | 1 | 2005 |
| Harvard University | Academic/Hospital | 5 | 4 | 4 | 1993 |
| Aarhus University | Academic/Hospital | 3 | 3 | 2 | 2005 |
| Ben Gurion University | Academic/Hospital | 3 | 2 | 2 | 2006 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 3 | 2006 |
| Saarland University | Academic/Hospital | 3 | 3 | 1 | 2009 |
| Sun Yat-Sen University | Academic/Hospital | 3 | 3 | 1 | 2009 |
| University of Bergen | Academic/Hospital | 3 | 1 | 2 | 1999 |
| All India Institute of Medical Sciences | Academic/Hospital | 2 | 1 | 2 | 2012 |
| Emisphere Technologies, Inc. | For profit | 2 | 2 | 1 | 2008 |
| Foundation for Anesthesia Education and Research | Academic/Hospital | 2 | 0 | 1 | 2008 |
| Foundation to Promote Research into Functional Vitamin B12 Deficiency, Bergen, Norway | Academic/Hospital | 2 | 0 | 2 | 1998 |
| Genentech | For profit | 2 | 0 | 1 | 2006 |
| Georgetown University | Academic/Hospital | 2 | 1 | 2 | 1999 |
| Government of Norway | Government | 2 | 0 | 2 | 1998 |
| HumanN | For profit | 2 | 1 | 2 | 2016 |
| Merck | For profit | 2 | 1 | 1 | 1998 |
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2004 |
| National Institute on Aging (NIA) | Government | 2 | 2 | 1 | 2000 |
Marketing (70)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abraxis | For profit | MKTG | Nov 6, 1981 |
| Abraxis | For profit | NDA2 | Nov 6, 1981 |
| Accord Research | For profit | MKTG | Sep 20, 1972 |
| Akorn, Inc. | For profit | MKTG | — |
| American Home Products | For profit | MKTG | Mar 21, 1973 |
| Apotex | For profit | MKTG | Apr 9, 2026 |
| Armour & Company | For profit | MKTG | Feb 22, 1980 |
| Armour & Company | For profit | NDA2 | Feb 22, 1980 |
| Aurobindo Pharma | For profit | MKTG | Dec 8, 2020 |
| Bayer | For profit | NDA2 | Sep 15, 1949 |
| Belmar Pharmacy | For profit | NDA2 | Jul 14, 1958 |
| Bracco | For profit | MKTG | Dec 21, 1970 |
| Bracco | For profit | NDA2 | Dec 21, 1970 |
| Bristol-Myers Squibb | For profit | NDA2 | Sep 29, 1950 |
| Del Laboratories | For profit | MKTG | Jun 22, 1973 |
| Dr. Reddy's Laboratories | For profit | MKTG | Jan 29, 1974 |
| Eli Lilly | For profit | MKTG | Jul 9, 1973 |
| Endo Pharmaceuticals | For profit | MKTG | Nov 5, 1996 |
| Endo Pharmaceuticals | For profit | NDA2 | Jan 31, 2005 |
| Eugia Pharma | For profit | MKTG | Dec 8, 2020 |
| Exeltis | For profit | MKTG | Aug 20, 2021 |
| Fosun | For profit | MKTG | Sep 24, 2020 |
| Fresenius | For profit | MKTG | Jun 20, 1973 |
| General Electric | For profit | MKTG | Jun 10, 1974 |
| General Electric | For profit | NDA2 | Jun 10, 1974 |
| Gland Pharma Ltd | For profit | MKTG | Sep 24, 2020 |
| Gland Pharma Ltd | For profit | SYN | Sep 24, 2020 |
| Hospira | For profit | MKTG | Feb 20, 1953 |
| Hospira | For profit | NDA2 | Feb 20, 1953 |
| Lupin | For profit | MKTG | Jun 30, 2023 |
| Lutipold | For profit | MKTG | Apr 26, 1972 |
| Lyphomed, Inc. | For profit | MKTG | Sep 12, 1979 |
| Mallinckrodt | For profit | MKTG | Jun 21, 1968 |
| Mallinckrodt | For profit | NDA2 | Jun 21, 1968 |
| Mankind Pharma | For profit | MKTG | Jul 10, 2024 |
| Meitheal | For profit | MKTG | Nov 15, 2024 |
| Merck | For profit | NDA2 | — |
| Mylan | For profit | MKTG | Sep 23, 2003 |
| Mylan | For profit | SYN | Jun 5, 2017 |
| Nanjing King-Friend | For profit | MKTG | Nov 15, 2024 |
| Nichi-Iko Pharmaceutical Co., Ltd. | For profit | MKTG | Nov 15, 2022 |
| Novartis | For profit | NDA2 | May 18, 2000 |
| Novartis | For profit | MKTG | Jan 4, 2021 |
| PH HEALTH | For profit | MKTG | Jul 27, 2007 |
| PHARMOBEDIENT | For profit | MKTG | Jun 5, 2017 |
| Padagis Us | For profit | MKTG | Sep 9, 2020 |
| Par Pharmaceuticals | For profit | NDA2 | Nov 5, 1996 |
| Perrigo | For profit | MKTG | Sep 9, 2020 |
| Pharmacia & Upjohn | For profit | NDA2 | — |
| Roche | For profit | MKTG | Jul 28, 1947 |
| Roche | For profit | NDA | Jul 28, 1947 |
| SOLOPAK | For profit | MKTG | — |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Nov 15, 2022 |
| Sandoz | For profit | SYN | Jan 4, 2021 |
| Sandoz | For profit | MKTG | May 18, 2000 |
| Sandoz | For profit | NDA2 | May 18, 2000 |
| Sankyo | For profit | MKTG | Apr 26, 1972 |
| Sanofi-Aventis | For profit | MKTG | Apr 7, 1982 |
| Savage Labs | For profit | MKTG | — |
| Sola Pharms | For profit | MKTG | Apr 15, 2022 |
| Somerset Pharmaceuticals | For profit | MKTG | Dec 11, 2015 |
| Teligent Pharmaceuticals | For profit | NDA2 | — |
| Vitruvias Therapeutics | For profit | MKTG | Dec 18, 2018 |
| Warner Chilcott | For profit | MKTG | Dec 6, 1949 |
| Warner Chilcott | For profit | NDA2 | Dec 6, 1949 |
| Watson Pharmaceuticals | For profit | MKTG | Jan 29, 1974 |
| Watson Pharmaceuticals | For profit | NDA2 | Jul 13, 1982 |
| West-Ward Pharmaceutical | For profit | SYN | Apr 12, 1974 |
| West-Ward Pharmaceutical | For profit | MKTG | Oct 20, 1971 |
| Zydus Discovery DMCC | For profit | MKTG | Apr 15, 2022 |